AVAX Technologies, Inc. Files Form 10 With SECBy Avax Technologies Inc., PRNE
Thursday, February 3, 2011
PHILADELPHIA, February 4, 2011 - AVAX Technologies, Inc. (Pink Sheets: AVXT) ("AVAX" or the "Company")
today announced that it filed a Form 10 with the Securities and Exchange
Commission ("SEC"). Upon the effectiveness of this Form 10, AVAX will once
again become a publicly reporting company. The Company intends to seek to
have its common stock trade on the Over-the-Counter Bulletin Board. The
Company's Form 10, which contains among other things, recent information
about the Company's business, operations, financial results and
capitalization, can be accessed through the website maintained by the SEC at
About AVAX Technologies, Inc.
AVAX Technologies, Inc. is a biotechnology company headquartered in
Philadelphia, PA. The Company is engaged in the research and clinical and
commercial development of biological products and cancer therapeutics. The
Company's AC Vaccine platform is a therapeutic cancer vaccine.
Certain statements in this release are "forward-looking" statements.
Forward-looking statements involve significant risks and uncertainties, and
in light of the significant uncertainties inherent in such statements, the
inclusion of such information should not be regarded as a representation by
the Company that the objectives and plans of the Company will be achieved. In
fact, actual results could differ materially from those contemplated by such
forward-looking statements. These statements include, but are not limited to,
the Company's immediate need to obtain additional funding to continue to
finance the Company, the Company's plans, objectives, projections,
expectations and intentions such as those relating to the future development
of M-VAX(R) and its other vaccine candidates, as well as other important
factors discussed in the Company's Form 10. The Company does not undertake
any obligation to release publicly any revisions to these forward-looking
statements or to reflect the occurrence of unanticipated events.
Jamie Bittenbender, AVAX Technologies, Inc., +1-215-241-9760
Tags: Avax Technologies Inc., February 4, Pennsylvania, Philadelphia